Pharmacyclics acquisition strengthens AbbVie pipeline, says Kalorama

US pharma company AbbVie's (NYSE: ABBV) recent acquisition of Pharmacyclics (Nasdaq: PCYC) for $21 billion (The Pharma Letter March 5) strengthens AbbVie's already comprehensive pipeline and increases the company's growth prospects, according to Kalorama Information.

Kalorama's Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies such as AbbVie. This report provides long-term company sales forecasts based on recent market conditions.

With the acquisition, AbbVie gains Pharmacyclics' flagship asset Imbruvica (ibrutinib), a highly effective treatment for hematologic malignancies, accelerating AbbVie's presence in oncology. This strengthens AbbVie's already robust pipeline and establishes a leadership position in the hematological oncology market, which now approaches $24 billion globally, says Kalorama.